|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5324731A
(en)
|
1989-02-14 |
1994-06-28 |
Amira, Inc. |
Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
|
|
US5676978A
(en)
|
1989-02-14 |
1997-10-14 |
Amira, Inc. |
Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
|
|
US6040138A
(en)
|
1995-09-15 |
2000-03-21 |
Affymetrix, Inc. |
Expression monitoring by hybridization to high density oligonucleotide arrays
|
|
US5215882A
(en)
|
1989-11-30 |
1993-06-01 |
Ortho Diagnostic Systems, Inc. |
Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5837832A
(en)
|
1993-06-25 |
1998-11-17 |
Affymetrix, Inc. |
Arrays of nucleic acid probes on biological chips
|
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
|
EP0735144B1
(en)
|
1995-03-28 |
2002-06-05 |
Japan Science and Technology Corporation |
Method for molecular indexing of genes using restriction enzymes
|
|
US5843974A
(en)
*
|
1995-06-06 |
1998-12-01 |
Eli Lilly And Company |
Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
|
|
US5958342A
(en)
|
1996-05-17 |
1999-09-28 |
Incyte Pharmaceuticals, Inc. |
Jet droplet device
|
|
US6060240A
(en)
|
1996-12-13 |
2000-05-09 |
Arcaris, Inc. |
Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
|
|
US6090556A
(en)
|
1997-04-07 |
2000-07-18 |
Japan Science & Technology Corporation |
Method for quantitatively determining the expression of a gene
|
|
US5994076A
(en)
|
1997-05-21 |
1999-11-30 |
Clontech Laboratories, Inc. |
Methods of assaying differential expression
|
|
WO1999031227A2
(en)
|
1997-12-12 |
1999-06-24 |
The University Of Western Ontario |
NOVEL PEPTIDE, apoEp1.B, COMPOSITIONS AND USES THEREOF
|
|
US6004755A
(en)
|
1998-04-07 |
1999-12-21 |
Incyte Pharmaceuticals, Inc. |
Quantitative microarray hybridizaton assays
|
|
US6048695A
(en)
|
1998-05-04 |
2000-04-11 |
Baylor College Of Medicine |
Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
|
|
US6087112A
(en)
|
1998-12-30 |
2000-07-11 |
Oligos Etc. Inc. |
Arrays with modified oligonucleotide and polynucleotide compositions
|
|
US6316503B1
(en)
|
1999-03-15 |
2001-11-13 |
Tularik Inc. |
LXR modulators
|
|
US8257750B2
(en)
|
1999-04-30 |
2012-09-04 |
Kibow Biotech, Inc. |
Calcium carbonate compositions for preventing or treating hyperphosphatemia
|
|
AU2001280576A1
(en)
|
2000-07-18 |
2002-01-30 |
Uab Research Foundation |
Tissue-specific self-inactivating gene therapy vector
|
|
US20030027335A1
(en)
|
2000-09-07 |
2003-02-06 |
Ruley H. Earl |
Genome engineering by cell-permeable DNA site-specific recombinases
|
|
ATE283253T1
(de)
|
2000-09-18 |
2004-12-15 |
Glaxo Group Ltd |
Substituierte aminopropoxyarylderivate als lxr agonisten
|
|
WO2002048197A1
(en)
|
2000-12-13 |
2002-06-20 |
Sca Hygiene Products Zeist B.V. |
Process for oxidising primary alcohols
|
|
JP2003033179A
(ja)
|
2001-07-05 |
2003-02-04 |
Asahi Kasei Corp |
可逆的遺伝子導入ベクター
|
|
US7247748B2
(en)
|
2002-03-27 |
2007-07-24 |
Smithkline Corporation |
Amide compounds and methods of using the same
|
|
US7560586B2
(en)
|
2002-03-27 |
2009-07-14 |
Smithkline Beecham Corporation |
Acid and ester compounds and methods of using the same
|
|
US7365085B2
(en)
|
2002-03-27 |
2008-04-29 |
Smithkline Beecham Corporation |
Compounds and methods
|
|
EP1552010B1
(en)
|
2002-07-19 |
2010-06-09 |
Althea Technologies, Inc. |
Strategies for gene expression analysis
|
|
US7135575B2
(en)
*
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
|
WO2004078939A2
(en)
|
2003-03-03 |
2004-09-16 |
University Of Massachusetts |
REGULATION OF Mdm2 FUNCTION
|
|
WO2005007877A2
(en)
|
2003-07-18 |
2005-01-27 |
University Of Massachusetts |
Regulatable promoters for synthesis of small hairpin rna
|
|
CA2543189A1
(en)
|
2003-10-20 |
2005-05-06 |
Nsgene A/S |
In vivo gene therapy of parkinson's disease
|
|
EP2284157A1
(en)
|
2003-12-12 |
2011-02-16 |
Wyeth |
Quinolines useful in treating cardiovascular disease
|
|
FR2865736B1
(fr)
|
2004-02-02 |
2006-07-14 |
Synt Em |
Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
|
|
US20050289659A1
(en)
|
2004-05-18 |
2005-12-29 |
Jacks E T |
Cre-lox based method for conditional RNA interference
|
|
CA2572872C
(en)
*
|
2004-07-02 |
2013-10-22 |
Sankyo Company Limited |
Tissue factor production inhibitor
|
|
JP2008505905A
(ja)
|
2004-07-07 |
2008-02-28 |
メルク エンド カムパニー インコーポレーテッド |
ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法
|
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
|
JP4620123B2
(ja)
|
2004-10-01 |
2011-01-26 |
エフ．ホフマン−ラ ロシュ アーゲー |
ヘキサフルオロイソプロパノール置換エーテル誘導体
|
|
AU2005318539B2
(en)
|
2004-12-22 |
2009-01-08 |
F. Hoffmann-La Roche Ag |
Novel cyclohexane derivatives
|
|
MX2007008370A
(es)
|
2005-01-10 |
2007-08-21 |
Astrazeneca Ab |
Derivados de 1,1-dioxidos de isotiazol-3 (2h) -ona como moduladores del receptor del higado x.
|
|
SE0500056D0
(sv)
|
2005-01-10 |
2005-01-10 |
Astrazeneca Ab |
Therapeutic agents 4
|
|
SE0500055D0
(sv)
|
2005-01-10 |
2005-01-10 |
Astrazeneca Ab |
Therapeutic agents 3
|
|
SE0500058D0
(sv)
|
2005-01-10 |
2005-01-10 |
Astrazeneca Ab |
Therapeutic agents 5
|
|
EP1838685A4
(en)
|
2005-01-10 |
2010-01-27 |
Astrazeneca Ab |
DERIVATIVES OF ISOTHIAZOL-3- (2H) -THION-1,1-DIOXIDES AS LIVER-X RECEPTOR MODULATORS
|
|
JP2008531709A
(ja)
|
2005-03-01 |
2008-08-14 |
ワイス |
シンノリン化合物および肝臓ｘ受容体調節物質としてのそれらの使用
|
|
JP2008533200A
(ja)
|
2005-03-21 |
2008-08-21 |
メルク エンド カムパニー インコーポレーテッド |
置換アリールおよびヘテロアリール誘導体、かかる化合物を含有する組成物および使用法
|
|
JP5237799B2
(ja)
|
2005-06-27 |
2013-07-17 |
エグゼリクシス パテント カンパニー エルエルシー |
ピラゾールベースのｌｘｒモジュレーター
|
|
DE602006021205D1
(de)
|
2005-10-07 |
2011-05-19 |
Exelixis Inc |
Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
|
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
|
US7790745B2
(en)
|
2005-10-21 |
2010-09-07 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinoline LXR Modulators
|
|
CA2627900A1
(en)
|
2005-11-14 |
2007-08-16 |
Irm Llc |
Compounds and compositions as lxr modulators
|
|
WO2007081335A1
(en)
|
2006-01-12 |
2007-07-19 |
Merck & Co., Inc. |
Therapeutic compounds for treating dyslipidemic conditions
|
|
ATE495197T1
(de)
|
2006-03-20 |
2011-01-15 |
Cepep Iii Ab |
Chimäre konstrukte zwischen auf krebs zielenden peptiden und zellpenetrierenden peptiden gekoppelt an antikrebsmittel und/oder diagnostische mittel
|
|
US20100048944A1
(en)
*
|
2006-07-19 |
2010-02-25 |
Farhad Parhami |
Interactions of hedgehog and liver x receptor signaling pathways
|
|
TW200825054A
(en)
|
2006-10-18 |
2008-06-16 |
Wyeth Corp |
Quinoline compounds
|
|
US8324367B2
(en)
|
2006-11-03 |
2012-12-04 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
|
CN101595096B
(zh)
|
2006-11-30 |
2012-06-27 |
兴和株式会社 |
取代甲醇化合物
|
|
CN101679297B
(zh)
|
2006-12-08 |
2012-01-11 |
埃克塞利希斯股份有限公司 |
Lxr和fxr调节剂
|
|
JP2008179562A
(ja)
|
2007-01-24 |
2008-08-07 |
Kowa Co |
Ｌｘｒアゴニスト
|
|
US8993628B2
(en)
|
2007-02-23 |
2015-03-31 |
City Of Hope |
Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof
|
|
MX2009012474A
(es)
|
2007-05-18 |
2009-12-18 |
Wyeth Corp |
Compuestos de quinazolina.
|
|
AU2008271050B2
(en)
|
2007-06-29 |
2014-11-06 |
Sarepta Therapeutics, Inc. |
Tissue specific peptide conjugates and methods
|
|
CA2695088C
(en)
|
2007-08-13 |
2013-03-12 |
F. Hoffmann-La Roche Ag |
Novel piperazine amide derivatives
|
|
TW200922582A
(en)
|
2007-08-20 |
2009-06-01 |
Organon Nv |
N-benzyl, N'-arylcarbonylpiperazine derivatives
|
|
US8039493B2
(en)
|
2007-09-27 |
2011-10-18 |
Hoffmann-La Roche Inc. |
Biaryl sulfonamide derivatives
|
|
DK2205737T3
(da)
*
|
2007-10-04 |
2013-05-21 |
Santaris Pharma As |
Mikromirer
|
|
MX2010005104A
(es)
|
2007-11-09 |
2010-08-04 |
Peregrine Pharmaceuticals Inc |
Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
|
|
US8236753B2
(en)
*
|
2007-12-10 |
2012-08-07 |
The Brigham And Women's Hospital, Inc. |
RAP variants for drug delivery and methods of use thereof
|
|
WO2009086130A1
(en)
|
2007-12-21 |
2009-07-09 |
Wyeth |
Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
|
|
US20110112135A1
(en)
|
2007-12-21 |
2011-05-12 |
Singhaus Jr Robert Ray |
Imidazo [1,2-A] Pyridine Compounds
|
|
JP2011507905A
(ja)
|
2007-12-21 |
2011-03-10 |
ワイス・エルエルシー |
ベンズイミダゾール化合物
|
|
EP2235020A1
(en)
|
2007-12-21 |
2010-10-06 |
Wyeth LLC |
Pyrazolo [1,5-a] pyrimidine compounds
|
|
EP2248811B1
(en)
|
2008-02-29 |
2012-11-14 |
Kowa Company, Ltd. |
2-oxochromene derivative
|
|
AU2009255357A1
(en)
*
|
2008-05-29 |
2009-12-10 |
Bristol-Myers Squibb Company |
Methods for predicting patient response to modulation of the co-stimulatory pathway
|
|
EP2303304A4
(en)
*
|
2008-07-01 |
2011-09-21 |
Cognosci Inc |
METHOD FOR THE TREATMENT OF CANCER WITH APOE PEPTIDES
|
|
BRPI0919377A2
(pt)
|
2008-09-26 |
2016-09-27 |
Dana Farber Cancer Inst Inc |
anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
|
|
US20120156216A1
(en)
*
|
2009-03-02 |
2012-06-21 |
Youngman Oh |
Methods and Compositions for Treatment of Tumor Metastasis
|
|
CA2761934C
(en)
*
|
2009-05-28 |
2018-01-09 |
Exelixis Patent Company Llc |
Substituted 1-(biphenyl-4-yl)-2-benzyl-4-hydroxyalkyl-1h-imidazole compounds and their use as lxr modulators
|
|
WO2011115892A1
(en)
*
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
|
WO2011130426A2
(en)
*
|
2010-04-13 |
2011-10-20 |
New York University |
Compositions and methods for treatment of melanoma
|
|
WO2011158667A1
(ja)
|
2010-06-16 |
2011-12-22 |
国立大学法人浜松医科大学 |
大腸腫瘍の検出方法
|
|
EP2474617A1
(en)
*
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
|
US20130004481A1
(en)
*
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
AR088728A1
(es)
|
2011-03-25 |
2014-07-02 |
Bristol Myers Squibb Co |
Moduladores de lxr como prodroga de imidazol
|
|
US20130071403A1
(en)
*
|
2011-09-20 |
2013-03-21 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
|
CA2882292C
(en)
*
|
2012-08-13 |
2023-10-17 |
The Rockefeller University |
Treatment and diagnosis of melanoma
|